An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic HCV-1 and HIV-1

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004928-35

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to assess the antiviral efficacy of telaprevir, Peg-IFN-alfa-2a, and RBV in HCV-1/HIV-1 coinfected subjects as measured by sustained virologic response (SVR12planned). SVR12planned is defined as having HCV RNA levels < 25 IU/mL 12 weeks after the last planned dose of HCV study medication.


Critère d'inclusion

  • Chronic Hepatitis C Infection